A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

Haematologica. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245. Epub 2014 Nov 25.
No abstract available

Keywords: AML; drug resistance; eIF4E; phase I; ribavirin.

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Cytarabine / administration & dosage
  • Drug Resistance, Neoplasm / drug effects*
  • Eukaryotic Initiation Factor-4E / metabolism*
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / metabolism
  • Leukemia, Myeloid, Acute / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Prognosis
  • Ribavirin / administration & dosage
  • Salvage Therapy*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Eukaryotic Initiation Factor-4E
  • Cytarabine
  • Ribavirin